New hope for liver cancer: drug targets tumors resistant to immunotherapy

NCT ID NCT07151326

Not yet recruiting Disease control Sponsor: National Health Research Institutes, Taiwan Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after first-line immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers that predict response or resistance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib (Cabometyx®)
What this could lead to: If successful, this could provide a treatment option for liver cancer patients who no longer respond to standard immunotherapy combinations.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply broadly. Cabozantinib can cause side effects like fatigue, diarrhea, and high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Chang Gung Memorial Hospital (Lin-Kou),

Taoyuan, Taiwan
Chang-Gung Memorial Hospital, Kaohsiung

Kaohsiung City, Taiwan
China Medical University Hospital

Taichung, Taiwan
Mackay Memorial Hospital

Taipei, 104, Taiwan
National Cheng-Kung University Hospital

Tainan, Taiwan
National Taiwan University Hospital

Taipei, 100, Taiwan
Taichung Veterans General Hospital

Taichung, 407, Taiwan
Taipei Veterans General Hospital

Taipei, Taiwan
Tri-Service General Hospital

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.